Showing 241-250 of 1560 results for "".
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
https://reachmd.com/programs/project-oncology/car-t-and-bispecifics-in-lbcl-redefining-second-line-therapy-choices/35457/The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategiXenotransplantation: History and Current Advances Part 1 of 2
https://reachmd.com/programs/advances-in-transplantation/xenotransplantation-history-and-current-advancesbr-part-1-of-2/6529/The necessity for transplantation of living cells from other species, or xenotransplantation, may arise when human donors are not available, a bridge organ is needed, or animal cells can provide a unique benefit to patients. Host Dr. Aaron Carroll's guests are xenotransplantation experts Dr. Paul HeCAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
https://reachmd.com/programs/project-oncology/car-t-and-bispecifics-in-lbcl-redefining-second-line-therapy-choices/36485/The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategiBiosimilars for the Treatment of Psoriasis
https://reachmd.com/programs/dermconsult/biosimilars-for-the-treatment-of-psoriasis/15986/Psoriasis is an autoimmune condition that causes the immune system to attack healthy skin cells, which leads to buildup of dead skin cells on the surface of the skin.Exploring the Role of MET Aberrations in NSCLC: Pathways to Personalized Care
https://reachmd.com/programs/clinicians-roundtable/exploring-the-role-of-met-aberrations-in-nsclc-pathways-to-personalized-care/26563/Hear expert insights on the MET pathway and the impact on patients with non-small cell lung cancer.Tying Reflux Disease to Pulmonary Symptoms
https://reachmd.com/programs/hot-topics-in-allergy/tying-reflux-disease-to-pulmonary-symptoms/3915/Gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) are both conditions stemming from acid reflux, but can manifest with different symptoms. What other health problems can be tied to LPR and GERD, and how can we determine the difference between the two? Dr. Clifford Bassett, asDiagnosing and Tracking the Progression of MacTel Type 2
https://reachmd.com/programs/cme/Diagnosing-and-Tracking-the-Progression-of-MacTel-Type-2/35964/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.Anatomy Meets Function – Correlating Imaging with Symptoms
https://reachmd.com/programs/cme/Anatomy-Meets-Function-Correlating-Imaging-with-Symptoms/35966/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.An Overview of Current Management Limitations
https://reachmd.com/programs/cme/An-Overview-of-Current-Management-Limitations/35968/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.MacTel Type 2: A Misnomer?
https://reachmd.com/programs/cme/MacTel-Type-2-A-Misnomer/35969/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.